Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies

Hans Jochem Kolb, Belinda Simoes, Christoph Schmid

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Purpose of review: The chimeric state after allogeneic stem cell transplantation provides an ideal platform for adoptive immunotherapy of hematologic malignancies using donor-derived cells. The present review aims to summarize recent results of the transfusion of donor-derived cells with regard to the diseases treated, the cells used for treatment, and the origin of these cells. Recent findings: The transfusion of donor lymphocytes has been studied widely, not only in patients with recurrent disease, persistent disease, and mixed chimerism but also in a variety of hematologic malignancies. Donors of lymphocytes and hematopoietic stem cells have been HLA-identical siblings, HLA-matched unrelated donors, and HLA-different haploidentical family members. A variety of cells have been used for adoptive immunotherapy, including plain lymphocytes, selected T cells, T cell lines, and T cell clones. The possible therapies have been expanded by natural killer cells and natural killer T cells as well as antibodies directing the effector cells toward the malignancy. Summary: Adoptive immunotherapy in chimeras has become not only a routine form of treatment of recurrent hematologic malignancy but also a prophylactic measure in high-risk leukemia and lymphoma.

Original languageEnglish
Pages (from-to)167-173
Number of pages7
JournalCurrent Opinion in Oncology
Issue number2
StatePublished - Mar 2004
Externally publishedYes


  • Donor lymphocytes
  • Stem cell transplantation


Dive into the research topics of 'Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies'. Together they form a unique fingerprint.

Cite this